betthera is ready for cost-benefit and health technology assessments in Horizon Europe (Health topics – Cluster 1)
How can betthera improve Horizon Europe Health proposals and make the project outcomes better prepared for the adoption by the healthcare system?
HORIZON-HLTH-DISEASE-2021-04-01: Comparative effectiveness research for healthcare interventions in areas of high public health need – betthera delivers assessments of innovative health technologies (HTAs) at national level and accelerate the practical implementation of the results. betthera developed 2 models which convert social and healthcare impacts to metrics. Those models could be enlarged with new data for the cost of intervention. We are particularly engaged for deployments in CEE countries and in searching of inflation point for introduction of new methods.
HORIZON-HLTH-DISEASE-2021-04-02: Building a European innovation platform for the repurposing of medicinal products – Transparent, evidence-based selection mechanisms for prioritisation of re-purposing projects, based on results of cost benefit calculation, cost estimation of the next steps, probability estimation. betthera deep experience is in rare diseases and in age-related diseases.
HORIZON-HLTH-DISEASE-2021-04-04: Artificial Intelligence for treatment and care – The economical assessment of health outcomes for optimised personalised treatments and a risk assessment linked to various AI solutions. betthera has experience of the cost evaluation of robotic, AI and medtech solutions for Alzheimer and heart failure patient care.
HORIZON-HLTH-CARE-2021-05-02: Data-driven decision-support tools for better health and care delivery and for policy-making – HTA and cost-effectiveness of individual interventions enabling the evidence-based participative decision-making processes and the design of the overall decision system.
HORIZON-HLTH-IND-2021-07-02: New payment models for cost-effective and affordable health innovations/new models of pricing – Cost-effectiveness and budget impact, including long term intended and unintended consequences of pricing and reimbursement decisions.
and others e.g.: HORIZON-HLTH-TOOL-2021-06-03: Innovative tools for use and re-use of health data or HORIZON-HLTH-TOOL-2021-06-02: Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet needs – Where betthera could perform the Cost Benefit Analysis (CBA) to show positive impact on society, describe all positives and negatives in qualitative way.